论文部分内容阅读
目的 研究两型 5α 还原酶同工酶在人前列腺癌组织中的表达情况及其意义。方法 应用逆转录 聚合酶链反应 (RT PCR)及免疫组化方法 ,对 15例正常前列腺组织 (取自尸体肾移植供体及全膀胱切除标本 )及 15例前列腺癌组织中两型 5α 还原酶的表达进行了定性和半定量研究。结果 正常及前列腺癌组织中都存在着两型 5α 还原酶mRNA及其酶蛋白的表达。Ⅰ型还原酶在腺癌组织中的表达明显高于正常组织 ,前列腺癌组织中Ⅱ型还原酶的表达相对较弱。Ⅰ型还原酶在前列腺癌组织中的表达水平与肿瘤的分期、分级及血清PSA水平存在正相关。结论 Ⅰ型 5α 还原酶在前列腺癌的发生、发展过程中起着重要作用 ,Ⅰ型 5α 还原酶抑制剂或两型 5α 还原酶的双重抑制剂可应用于前列腺癌的治疗。
Objective To study the expression of two types of 5α-reductase isozymes in human prostate cancer and its significance. Methods Reverse transcription polymerase chain reaction (RT PCR) and immunohistochemistry were used to detect the expression of two types of 5α-reductase in 15 cases of normal prostate tissue (donor from cadaveric kidney transplantation and total cystectomy) and 15 cases of prostate cancer The expression of a qualitative and semi-quantitative study. Results There were two types of 5α-reductase mRNA and its enzyme protein expression in normal and prostate cancer tissues. The expression of type Ⅰ reductase in adenocarcinoma was significantly higher than that in normal tissues. The expression of type Ⅱ reductase in prostate cancer was relatively weak. The expression level of type Ⅰ reductase in prostate cancer tissues is positively correlated with tumor stage, grade and serum PSA level. Conclusions Type Ⅰ 5α reductase plays an important role in the development of prostate cancer. Type Ⅰ 5α reductase inhibitors or dual inhibitors of both types of 5α reductase may be used in the treatment of prostate cancer.